SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Senior Staff Writer

Tristan is BioSpace‘s senior staff writer. Based in Metro Manila, Tristan has more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Harold Cunningham/Getty Images
Business
Novartis’ Restructuring Claims 285 Jobs in New Jersey
Novartis will eliminate 285 jobs across units in New Jersey. The terminations will take effect on January 28, 2023.
December 20, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Drug Development
bluebird’s SCD Gene Therapy Released from Partial Hold
The FDA lifted its partial clinical hold on bluebird’s experimental sickle cell disease gene therapy for patients younger than 18.
December 20, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Getty Images
Business
Lilly Plunks Down up to $731M in GPCR Pact with Sosei
Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
December 16, 2022
 · 
2 min read
 · 
Tristan Manalac
Business
In Second Pipeline Pivot, Axcella Axes 85% of Staff
In a strategic reorganization announced Thursday, Axcella Therapeutics will focus its resources on its Long COVID program and slash headcount by 85%.
December 15, 2022
 · 
2 min read
 · 
Tristan Manalac
Policy
FDA Adcomm Votes Against Cytokinetics’ Heart Failure Drug
The FDA’s Cardiovascular and Renal Drugs Advisory Committee stood against Cytokinetics, Inc., finding that the benefits of its heart failure hopeful didn’t outweigh its risks.
December 14, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy of Beigene
Drug Development
BeiGene’s Brukinsa Outshines Janssen’s Imbruvica in Comparison Trial
In a comparison trial, BeiGene’s Brukinsa bested Janssen’s Imbruvica in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL).
December 14, 2022
 · 
3 min read
 · 
Tristan Manalac
Maddie Meyer/Getty Images
Drug Development
Moderna and Merck’s mRNA Cancer Vaccine Aces Advanced Melanoma Study (Updated)
An investigational mRNA cancer vaccine developed by Moderna and Merck reached its primary efficacy endpoint, inducing a clinically meaningful improvement in recurrence-free survival.
December 13, 2022
 · 
2 min read
 · 
Tristan Manalac
Onivyde failed in the trial of late-stage small ce
FDA
Mirati Challenges Amgen in KRAS Space with FDA Accelerated Approval
Mirati gets the green light from the FDA for its KRAS G12C-mutated lung cancer medication.
December 13, 2022
 · 
2 min read
 · 
Tristan Manalac
Chris Hondros/Getty Images
Deals
Merck Officially Commences $1.36B Imago Buyout
Merck initiated a tender offer Monday to buy all outstanding shares of Imago Biosciences. This follows the November announcement of the buyout.
December 12, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy Artur Widak/NurPhoto via Getty Images
Deals
Amgen to Buy Horizon in Biotech’s Biggest Deal of 2022
Amgen confirmed Monday it will acquire rare disease giant Horizon Therapeutics for $26.4 billion.
December 12, 2022
 · 
2 min read
 · 
Tristan Manalac
Jonathan Weiss/Shutterstock
Drug Development
With Two Wins at SABCS, AstraZeneca Continues Breast Cancer Rally
AstraZeneca posted two mid-stage wins at the 2022 San Antonio Breast Cancer Symposium on Thursday, touting the efficacy of capivasertib and camizestrant against breast cancer.
December 9, 2022
 · 
2 min read
 · 
Tristan Manalac
Chesnot/Getty Images
Business
Sanofi Backs Out of Revolution Partnership in Latest Cancer Cull
Sanofi has terminated its global development and commercialization pact with Revolution Medicines, Inc. for their SHP2 inhibitor drug candidate,
December 8, 2022
 · 
2 min read
 · 
Tristan Manalac
courtesy of Shutterstock
Drug Development
‘Dramatic’ Placebo Effect Trips Relmada’s MDD Hopeful for the Second Time
Relmada’s investigational NDMA receptor channel blocker, REL-1017, failed to meet its primary endpoint in major depressive disorder in the Phase III RELIANCE I trial.
December 8, 2022
 · 
2 min read
 · 
Tristan Manalac
Courtesy Getty Images
Drug Development
Prometheus’ Anti-TL1A Monoclonal Antibody Notches Wins in Colitis, Crohn’s
Findings from the Phase II ARTEMIS-UC and Phase IIa APOLLO-CD trials show that Prometheus’ PRA023 is potentially safe and effective for treating ulcerative colitis and Crohn’s disease.
December 7, 2022
 · 
2 min read
 · 
Tristan Manalac
Business
Karuna Taps New CEO, Prepares to Submit NDA for Schizophrenia Candidate
Karuna Therapeutics appointed Bill Meury as its new president and chief executive officer, succeeding its current head, Steve Paul.
December 7, 2022
 · 
2 min read
 · 
Tristan Manalac
Load More